Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: an updated meta-analysis by Dan Li et al.
Li et al. BMC Ophthalmology 2014, 14:147
http://www.biomedcentral.com/1471-2415/14/147RESEARCH ARTICLE Open AccessHomocysteine, methylenetetrahydrofolate
reductase C677T polymorphism, and risk of
retinal vein occlusion: an updated meta-analysis
Dan Li1,2, Minwen Zhou3, Xiaoyan Peng1* and Huiyu Sun2Abstract
Background: To evaluate the role of plasma total homocysteine (tHcy) and homozygosity for the thermolabile
variant of the methylenetetrahydrofolate reductase (MTHFR) C677T genotype in the risk of retinal vein occlusion
(RVO).
Methods: Relevant studies were selected through an extensive search of PubMed, EMBASE, and the Web of
Science databases. Summary weighted mean differences (WMDs) or odds ratios (ORs) and 95% confidence intervals
(CI) were calculated with a random-effects model.
Results: Forty-two studies with 6445 participants were included in this updated systematic review and meta-analysis.
The mean plasma tHcy level in the RVO patients was significantly higher than in the controls (WMD =2.13 μmol/L;
95% CI: 1.29 to 2.98, P < 0.001), but there was evidence of between-study heterogeneity (P < 0.001). No significant
association between MTHFR C677T genotype and RVO was found under all genetic models.
Conclusion: There was some evidence that plasma tHcy is associated with an increased risk of RVO. There was no
evidence to suggest an association between homozygosity for the MTHFR C677T genotype and RVO.
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Retinal vein occlusion (RVO) is one of the most common
vision-threatening retinal vascular diseases, affecting males
and females almost equally and occurring most frequently
in elderly subjects [1,2]. It is a multifactorial disease, which
may affect small, medium, and large ocular vessels, with
central occlusion representing the most dangerous clinical
entity. Central retinal vein occlusion (CRVO) and branch
retinal vein occlusion are the most common and clinically
relevant types of venous occlusions. Arterial hypertension,
diabetes mellitus, cigarette smoking, atherosclerosis, and in-
creased plasma lipoprotein (a) have been reported as sys-
temic risk factors for RVO [3-7].
Homocysteine (Hcy), a sulfur-containing amino acid
formed during the metabolism of methionine, can be* Correspondence: drpengxy@163.com
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unless otherwise stated.remethylated to methionine throughmethyltetrahydrofo-
late reductase (MTHFR) [8]. Several studies have shown
that the level of plasma total homocysteine (tHcy) is ele-
vated in RVO patients and it is a risk factor for RVO
[9,10]. The MTHFR C677T gene mutation is an import-
ant cause of elevated plasma tHcy. The mutation results
in Hcy not being remethylated to methionine, leading to
hyperhomocysteinemia [11,12]. Although a number of
studies have reported a correlation between the MTHFR
C677T mutation and RVO, the role of the mutation in
the pathogenesis of RVO remains unclear [13,14].
A previous meta-analysis of 25 case–control studies con-
ducted in 2009 showed that elevated tHcy was associated
with RVO but not for the MTHFR C677T genotype [15].
However, this meta-analysis had some limitations, including
a lack of information on the dose-effect relationship be-
tween tHcy and RVO. Another meta-analysis on the associ-
ation of tHcy with RVO published in 2003 included only 19
case–control studies [16]. Since the meta-analysis washis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tionship has yielded inconsistent results [10,14,17-20].
In the present study, we analyzed the relation among
tHcy, the MTHFR C677T genotype, and RVO in an up-
dated meta-analysis of case–control studies. The aim of this
updated analysis of 42 studies was to derive a more precise
estimation of the relationship among tHcy, the MTHFR
C677T genotype, and the risk of RVO.
Methods
Literature search
A systematic literature search of PubMed, ISI Web of Sci-
ence, and EMBASE was performed to identify relevant
studies from inception until March 10, 2014. The follow-
ing terms were used in the searches: “retinal vein occlu-
sion” AND (“homocysteine” OR “methyltetrahydrofolate
reductase”). The websites of professional associations and
Google Scholar were also searched for additional informa-
tion. When relevant articles were identified, their refer-
ence lists were searched for additional articles. The final
search was carried out on March 10, 2014, without restric-
tions regarding publication year, language, or methodo-
logical filter.
Inclusion and exclusion criteria
Studies included in this meta-analysis met the following
criteria. The studies (a) contained a laboratory assessment
of plasma tHcy concentrations or reported odds ratio
(ORs) and their 95% confidence intervals (CIs) of the asso-
ciation between tHcy and RVO, or they assessed the
MTHFR C677T polymorphism. Alternatively, (b) articles
were retrieved if they were retrospective, prospective, or
case–control studies. If multiple publications from the
same study population were available, the most recent
study would be eligible for inclusion in the meta-analysis.
Editorials, letters to the editor, review articles, case re-
ports, meeting abstracts, and animal experimental studies
were excluded.
Data extraction
Two authors (Z.M.W. and X.Y.P.) independently extracted
the following data from the included studies: publication
data (author, year of publication, and country of the popu-
lation studied); patient condition (fasting status); partici-
pant’s age and sex; number of cases and controls; the Hcy
levels in the cases and the control subjects; the adjusted
ORs of the association between tHcy and RVO; and the
genotype counts.
Assessment of the quality of the methodology
Two reviewers independently assessed the quality of each
study using the Newcastle-Ottawa Scale (NOS) [21]. The
NOS uses a “star” rating system to judge quality based on
three aspects of the study: selection, comparability, andexposure. The scores ranged from 0 stars (worst) to 9 stars
(best). Studies with a score of ≥7 were considered of high
quality [22,23]. Any discrepancies were addressed by a
joint re-evaluation of the original article with a third re-
viewer (D. L).
Statistical analysis
The weighted mean differences (WMDs) were used to
compare the plasma tHcy concentrations between the case
and control subjects. The pooled adjusted ORs with their
corresponding 95% CIs were used as a common measure
of the association between tHcy and the risk of RVO. ORs
and 95% CIs were calculated for the MTHFR C677T TT
genotype exposure and RVO. The association between
MTHFR C677T genotype exposure and RVO was exam-
ined using the following genetic models: the homozygote
co-dominant (TT vs. CC), heterozygote co-dominant (TC
vs. CC), dominant genetic (TT/TC vs. CC), and recessive
genetic (TT vs. TC/CC) models.
We combined the data using a random effects model to
achieve more conservative estimates [24]. Statistical hetero-
geneity between the studies was evaluated using Cochran’s
Q test and the I2 statistic. For the Q statistic, P < 0.05 was
considered to indicate statistically significant heterogeneity.
A meta-regression analysis was used to investigate the in-
fluence of the variables on the study heterogeneity across
strata. To detect publication biases, we calculated Begg’s
and Egger’s measures [25,26]. A P value less than 0.05 was
considered statistically significant in the test for the overall
effect. The analysis was conducted using the Stata software
package (Version 12.0; Stata Corp., College Station, TX).
Sensitivity analysis
A subgroup analysis was used to investigate which fac-
tors (diagnosis, sources of controls, adjusting factors,
and overnight fasting status) might contribute to hetero-
geneity. Furthermore, we performed a sensitivity analysis
by excluding the low-quality studies and reanalyzing the
pooled estimate for the remaining studies.
Results
Literature search
The literature search identified 422 papers. Of these, 196
were excluded because they were duplicate studies. Ini-
tially, the title, abstract, and medical subject heading
words of the obtained publications were used for a rough
judgment on the eligibility of an article. In total, 168 stud-
ies, including reviews and case series, were excluded for
various reasons, such as being irrelevant to our analysis.
The remaining 58 were retrieved for a full-text review. In
total, 16 articles were excluded for various reasons. Of
these, seven articles were excluded because they provided
no data on plasma tHcy concentrations or the prevalence of
the MTHFR C677T genotype. Four articles were excluded
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levels, only reporting on the proportion of hyperhomocystei-
nemia (hyperhomocysteinemia defined as plasma tHcy
>15 μmol/L). Two articles were excluded because they were
cross-section studies. Two articles contained duplicated data
and one article compared the plasma tHcy concentrations
between single-episode CRVO patients and recurrent
CRVO patients. Finally, 42 case–control studies were in-
cluded in this meta-analysis [9,10,14,17-20,27-61]. The study
selection process is shown in Figure 1.
Study characteristics and quality assessment
All studies were case–control in design. Table 1 shows
the studies identified and their main characteristics. The
studies were published between 1998 and 2014, and they
originated from the United States, Israel, Sweden, the
United Kingdom, Ireland, Italy, Austria, Argentina, Saudi
Arabia, France, Iran, Turkey, Thailand, China, India, and
Brazil. In total, 2,794 cases and 3,651 controls were in-
cluded in the meta-analysis. The controls were mainly
healthy populations without retinal vascular disease. TheFigure 1 Flow diagram outlining the selection process for the inclusioNOS results showed that the average score was 7.11
(range 6–8), indicating that the methodological quality
was generally good (Table 1).
Plasma tHcy level outcomes
The analysis of the average plasma tHcy level of the RVO
patients and controls in 34 studies revealed significant het-
erogeneity (I2 = 93.8%, P < 0.001) across the articles. There-
fore, the data were pooled ina random-effects model. The
meta-analysis of these data showed that the plasma tHcy
level was significantly higher in the RVO patients than in
the controls (WMD =2.13 μmol/L; 95% CI: 1.29–2.98,
P < 0.001, Figure 2). Table 2 shows the detailed results
stratified by the characteristics of the study. Overall, the
plasma tHcy level was significantly higher in the RVO pa-
tients than in the control subjects, and this was consistently
observed in each subgroup. Moreover, there was evidence
of heterogeneity in all subgroups. Table 2 presents the re-
sults of the meta-regression analysis of the influence of the
key characteristics of the studies (subgroup factors) on het-
erogeneity. After the exclusion of low-quality studies, then of the studies in the systematic review and meta-analysis.
Table 1 Characteristics of enrolled case–control studies
















Salomon (1998) [59] Israel No 102 45 48 105 NA 58/44; 65/40 CP Hospital patients with
non-retinal vascular
diagnosis
Age MTHFR C677T 7
Glueck (1999) [25] United States No 17 NA NA 234 52/37 8/9;NA CP “Healthy subjects” NA MTHFR C677T 6




Larsson (2000) [27],a Sweden No 37 37 0 65 40.9/40.9 67/49; 110/30 HR “Randomly selected” Age tHcy, MTHFR C677T 8
79 79 0 88 69.6/69.6
Pianka (2000) [28] Israel No 21 21 0 81 58.6/66 NA CP “Healthy adults” Age, Sex tHcy 6
Martin (2000) [9] United Kingdom Yes 60 36 24 85 65.6/51.5 NA CP Laboratory staff/
hospital patients
NA tHcy 7
Cahill (2000) [29] Ireland Yes 61 40 21 87 69.2/70.2 29/32; 36/51 HR Hospital patients,
primarily cataract
extraction
Age tHcy, MTHFR C677T 8
Boyd (2001) [30] United Kingdom No 63 63 0 63 60.3/60.8 NA CP Hospital patients with
non-retinal vascular
diagnosis
Age tHcy, MTHFR C677T 8
Marcucci (2001) [31] Italy Yes 100 100 0 100 Median
59/ 56
54/46; 58/42 CP Friends/partners, no
cardiovascular disease
Age, Sex tHcy, MTHFR C677T 7
Weger (2002) [32] Austria Yes 84 0 84 84 68.1/68.2 37/47; 37/47 CP Hospital patients, Age tHcy, MTHFR C677T 8
Adamczuk (2002) [33] Argentina Yes 37 37 0 144 NA 17/20; 66/78 CP “Volunteers” Age, Sex MTHFR C677T 7
Brown (2002) [34] United States Yes 20b 15 3 20 69.1/69.5 12/8; 10/10 HR “Normal subjects” Age, Sex tHcy 8
Weger (2002) [35] Austria Yes 78 78 0 78 68.7/68.6 33/45; 33/45 HR Hospital patients Age, Sex tHcy, MTHFR C677T 8
El-Asrar (2002) [36] Saudi Arabia Yes 48 36 12 59 45.3/46.1 NA;44/15 CP “Healthy adults” Age, Sex tHcy 6
Blondel (2002) [58] France No 101 85 14 29 54/51.0 45/56; 13/16 CP Source not given Age tHcy 7
Marcucci (2003) [37] Italy Yes 55 26 29 61 Median
57/ 56
24/31; 27/34 CP Friends/partners, Age, Sex tHcy, MTHFR C677T 8
Parodi (2003) [38] Italy Yes 31 31 0 31 44.5/44.2 19/12; 19/12 CP “Volunteers” Age, Sex tHcy, MTHFR C677T 7
Dodson (2003) [39] United Kingdom NA 40 NA NA 40 Median
66.1/ 66
21/19; 21/19 CP “healthy adults” Age, Sex MTHFR C677T 7
Yaghoubi (2004) [40] Iran Yes 24 10 14 24 61.1/61. 7 11/13; 12/12 CP Hospital patients Age tHcy 6
Yildirim (2004) [41] Turkey Yes 33 9 20 25 61.0/58.0 15/18; 11/14 CP NA Age, Sex tHcy 7
Atchaneeyas-akul
(2005) [42]
Thailand Yes 32 11 15 88 53.8/54.4 19/22; 41/49 CP Volunteers Age, Sex tHcy 6


















Table 1 Characteristics of enrolled case–control studies (Continued)
McGimpsey (2005)
[44]
United Kingdom No 106 60 46 98 67.9/68.4 55/51; 45/53 HR Clinic patients /friends Age, Sex tHcy, MTHFR C677T 8
Gao(2006) [45] China Yes 64 64 0 64 59.5/59.5 33/31; 33/31 CP Volunteers Age, Sex, tHcy, MTHFR C677T 7
Gumus (2006) [46] Turkey Yes 82 26 56 78 57.7/57.4 36/46; 33/45 CP Patients with refractive
errors, presbyopia, or
cataract
Age, Sex tHcy 7
Lattanzio (2006) [47] Italy Yes 58 58 0 103 39.8/40.3 38/20; 59/44 CP Hospital staff Age, Sex tHcy 7
Pinna (2006) [48] Italy Yes 75 33 42 72 63.9/63.5 40/35; 37/35 CP Friends/partners/
hospital staff
Age, Sex tHcy 8
Narayanasam-y (2007)
[49]
India Yes 29 29 0 57 31.0/27.0 22/7; 41/16 CP Hospital staff/students Age, Sex tHcy 8
Biancardi (2007) [50] Brazil No 55 NA NA 55 NA 23/32; 23/32 CP Hospital patients Age, Sex MTHFR C677T 6
Moghimi (2008) [51] Iran Yes 54 54 0 51 59.8/63.0 32/22; 29/22 CP Clinic patients Age, Sex, tHcy 7




CP Healthy subjects Age, Sex tHcy 8
Di Capua (2010) [53] Italy Yes 117 NA NA 202 54.0/52.0 61/56; 105/97 CP Volunteers Age, Sex tHcy, MTHFR C677T 7
Pinna(2010) [54] Italy Yes 40 0 40 80 64.3/63.2 19/21; 38/42 CP “Normal subjects” Age, Sex tHcy 8
Sottilotta (2010) [14] Italy No 105 17 88 226 58.4/55.7 46/59; 44/182 CP Healthy participants Age MTHFR C677T 7
Pinna (2010) [55] Italy Yes 29 29 0 80 63.2/63.2 15/14; 38/42 CP Healthy participants Age, Sex tHcy 6
Tea (2013) [19] France No 21 21 0 23 46/46 14/7;15/8 CP Volunteers Age, Sex MTHFR C677T 7
Bharathi (2012) [56] India Yes 23 23 0 57 30.0/28.0 17/6; 38/16 CP Volunteers Age, Sex tHcy 6
Dong (2013) [18] China Yes 68 68 0 68 58.6/58.6 28/40; 28/40 CP Hospital patients Age, Sex tHcy, MTHFR C677T 7
Lahiri (2013) [10] India Yes 64 24 40 45 NA NA CP NA Age, Sex tHcy 7
Minniti (2014) [17] Italy Yes 91 47 44 71 57/55 51/40; 30/41 HR Volunteers Age, Sex tHcy, MTHFR C677T 7
Mrad(2014) [20] Tunisia Yes 72 NA NA 140 48.5/51.7 50/22; 95/45 HR Healthy participants Age tHcy, MTHFR C677T 7
Russo (2014) [57] Italy Yes 113 NA NA 104 NA 57/56; 75/29 CP Volunteer controls Age, Sex MTHFR C677T 6
aData presented in 2 age groups: <50 years and >50 years.
bIncludes others (e.g., hemi-retinal, hemispheric, macular).


















Figure 2 Meta-analysis of the average plasma tHcy level of the RVO patients and controls. WMD weighted mean difference, CI confidence
interval. (Larsson et al. [29]): Data presented for two age groups: <50 years and >50 years.







Study heterogeneity P for meta-
regressionχ2 P I2
Overnight fast 0.269
Yes 28 2.41 (1.41, 3.41) Z =4.71, P <0.001 481.24 <0.001 94.4%
No 7 1.20 (0.25, 2.16) Z =2.46, P =0.014 23.70 0.001 74.7%
Diagnosis 0.343
RVOa 18 2.56 (1.39, 3.72) Z =4.31, P <0.001 222.86 <0.001 92.4%
CRVO 17 1.67 (0.39, 3.00) Z =2.55, P =0.011 314.88 <0.001 94.9%
Source of cases 0.696
Hospital records 9 1.60 (0.47, 2.74) Z =2.76, P =0.006 52.86 <0.001 84.9%
Consecutive patients 26 2.24 (1.25, 3.23) Z =4.44, P <0.001 401.13 <0.001 93.8%
Adjusting factors 0.245
NA 1 4.30 (3.80, 4.80) Z =17.00, P <0.001 - - -
Age 10 1.33 (0.47, 2.18) Z =3.05, P =0.002 32.23 <0.001 72.1%
Age, sex 24 2.34 (1.19, 3.50) Z =3.98, P <0.001 409.41 <0.001 94.4%
aRVO subgroup includes CRVO, BRVO and others (e.g., hemi-retinal, hemispheric, macular).
tHcy = total homocysteine; WMD =weighted mean differences; CI = confidence interval; RVO = retinal vein occlusion; CRVO = central retinal vein occlusion.
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suggesting a high stability of the meta-analysis results
(WMD =2.35 μmol/L; 95% CI: 1.42–3.28, P < 0.001,
Figure 3). With regard to the plasma tHcy level outcomes,
Begg’s rank correlation test and Egger’s linear regression test
provided little evidence of publication biases among the
studies (Begg, P =0.091; Egger, P =0.051).
Association between plasma tHcy and RVO
We identified nine studies that reported an association be-
tween tHcy and RVO. As shown in Figure 4, a 1 μmol/L
increase in the plasma tHcy level was associated with an
OR of 1.14 (95% CI: 1.07–1.21) in the random-effects
model, showing a statistically significant association be-
tween tHcy and the risk of RVO. The heterogeneity was
statistically insignificant (I2 = 47.6%; P =0.054).
Association between the MTHFR C677T genotype
and RVO
The pooled ORs with their respective 95% CIs and the
result of the heterogeneity test are presented in Table 3
and Figure 5. Overall, there was no evidence of a signifi-
cant association between the MTHFR C677T genotypeFigure 3 Forest plot of the average plasma tHcy level of the RVO pat
weighted mean difference, CI confidence interval.and RVO in any genetic model tested (TT VS. CC/CT:
OR = 1.16, 95% CI =0.89–1.50; CC VS. TT/CT: OR = 1.02,
95% CI =0.73–1.41; TT VS. CC: OR = 1.30, 95% CI =0.85–
1.98; CT VS. CC: OR = 1.22, 95% CI = 0.90–1.66). The I2
statistic indicated substantial between-study heterogeneity
in all genetic models tested. For MTHFR, the Begg’s test
and Egger’s test also showed little evidence of publication
biases among the studies (Table 3).
Discussion
The present meta-analysis evaluated the relationship
among plasma tHcy, the MTHFR C677Tgenotype, and
RVO, and it included only case–control studies. The data
provide a greater ability to assess the potential correlation
between the aforementioned factors. We combined the ef-
fect sizes of 34 studies, which compared plasma tHcy
levels between RVO patients and controls, in a random-
effects model. The results demonstrated that the plasma
tHcy level was significantly higher in the RVO patients
than in the controls, with a pooled WMD of 2.13 μmol/L
(95% CI: 1.29–2.98). A meta-analysis of data collected be-
fore September 2009revealed that the mean tHcy in the
cases was 2.8 μmol/L (95% CI: 1.8–3.7) greater than in theients and controls after omitting the low-quality studies. WMD
Figure 4 Forest plot of the risk estimates of the association between plasma tHcy and RVO. OR odds ratio, CI confidence interval.
Li et al. BMC Ophthalmology 2014, 14:147 Page 8 of 11
http://www.biomedcentral.com/1471-2415/14/147controls [15]. Our findings are consistent with those of
the earlier meta-analysis. Of note, when we analyzed the
association between plasma tHcy and RVO, we found that
a 1 μmol/L increase in the plasma tHcy level was associ-
ated with an OR of 1.14. Moreover, in the present meta-
analysis, in an attempt to produce robust results, we
performed subgroup and sensitivity analyses based on
various characteristics of the study. The results of the sub-
group and sensitivity analyses did not materially alter the
pooled results, thereby supporting the robustness of our
main finding. The possible mechanisms by which tHcy
may contribute to RVO include the activation of factor V,
the increased oxidation of low-density lipoprotein, the in-
hibition of plasminogen activator binding, and the activa-
tion of protein C [62].
The previous meta-analysis investigated the association
between the MTHFR C677T genotype and RVO and
found no association between the homozygosity of the TT





OR (95% CI) P
x2
TT VS. CC/CT 23 1.16 (0.89–1.50) 0.268 36.66
CC VS. TT/CT 14 0.77 (0.57,1.05) 0.098 37.78
TT VS. CC 14 1.30 (0.85,1.98) 0.223 28.78
CT VS. CC 14 1.22 (0.90,1.66) 0.202 34.8
aP Egger’s test = the P value for Egger’s test.
bP Begg’s test = the P value for Begg’s test.possible cause of this lack of association was the modest
number of studies included in the meta-analysis. However,
with the added statistical power of 1,682 cases, the present
meta-analysis also found no significant association be-
tween the MTHFR C677T genotype and RVO under all
genetic models. Genetic factors are not the only factors
capable of increasing the tHcy level; demographic and life-
style factors, such as age, gender, folate intake, smoking
status, vitamin B levels, systemic vascular diseases, and
use of antihypertensive medications, can affect the plasma
tHcy level [63].
The present meta-analysis identified substantial hetero-
geneity among the studies. This was not surprising, given
the differences in the characteristics of the populations,
data collection methods, ethnic populations, sample size,
and sources of the cases. Whenever significant heterogen-
eity was present, a subgroup analysis was conducted, and
a random-effects model was used to pool the results.
However, our attempts to identify homogeneous subsetsHeterogeneity P Egger’s testa P Begg’s testb
I2 P
40.0% 0.026 0.551 1.000
65.6% <0.001 0.510 0.584
54.8% 0.007 0.056 0.063
62.6% 0.001 0.109 0.101
Figure 5 Forest plot of the risk estimates of the association between the MTHFR C677T genotype and RVO (recessive model, TT vs. TC/CC).
OR odds ratio, CI confidence interval.
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remaining in all the subgroups in the studies. The meta-
regression analysis also failed to identify the main sources
of the heterogeneity. Several factors might account for the
heterogeneity. First, environmental exposure and diet
might play roles [63]. Second, some unpublished, eligible
publications were unavailable for inclusion in the present
meta-analysis, and this might have affected the results.
Thus, the results should be considered with caution.
The previous meta-analysis analyzed data from 25 case–
control studies and found that plasma tHcy level was rela-
tively higher in RVO patients compared with controls
[15]. The authors also found no association between the
MTHFR C677T genotype and RVO. However, the meta-
analysis contained a number of weaknesses. First, the
authors reported the difference in the plasma tHcy level
between the cases and controls, but not the dose-effect re-
lationship between tHcy and RVO. In the present meta-
analysis, we found that a 1 μmol/L increase in the plasma
tHcy level was associated with an OR of 1.14. In addition,
the previous meta-analysis did not have rigorous inclusion
criteria [15]. For example, they included a case series
study, and they only indirectly compared the cases and
controls [64].The results of the present meta-analysis must be inter-
preted cautiously in light of the strengths and limitations of
the included studies. A major strength of this study is the
enlarged sample size, as compared to the previous meta-
analysis, and we added 17 newly published case–control
studies, which provides enhanced statistical power and of-
fers more precise and reliable effect estimates. Furthermore,
we only included the case–control studies and no other
studies. In addition, the methodological issues for the meta-
analysis, such as publication bias and the stability of results,
were well investigated. Our meta-analysis also has several
limitations. One potential limitation is the substantial het-
erogeneity observed among the studies. Second, the case–
control study design means that the assessment of tHcy in
patients at varying time intervals after the occlusive vascu-
lar event is methodologically weak. The vascular occlusive
event itself could increase the tHcy concentration. Third, to
avoid publication bias, we performed not only an electronic
search but also a manual search to identify all potentially
relevant papers, including published and non-published
sources. Unfortunately, we may have failed to include some
papers, especially those published in other languages. Publi-
cation bias may have resulted in an overestimate of the rela-
tionship between tHcy and RVO. Fourth, in some studies,
Li et al. BMC Ophthalmology 2014, 14:147 Page 10 of 11
http://www.biomedcentral.com/1471-2415/14/147age was not entirely matched between the case and con-
trol groups. There is some evidence that tHcy increases
with age, which might have affected the pooled results.
Fifth, the controls were not uniformly defined. This was a
meta-analysis of case–control studies, and no studies were
population-based. Thus, some inevitable selection biases
might exist in the results, and they may not be representa-
tive of the general population.
Conclusions
In conclusion, despite these limitations, the current meta-
analysis of observational studies suggests that an elevated
level of plasma tHcy increases the risk of RVO. There was
no evidence to suggest an association between the MTHFR
C677T genotype and RVO. Despite these encouraging find-
ings, the inherent limitations of the included studies should
be considered, and conclusions drawn from our pooled re-
sults should be interpreted with caution.
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